Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
The tumor blood testing market is gaining significant traction as advances in medical technology and rising cancer rates drive demand for less invasive diagnostic options. With continuous innovations and expanding applications, this sector is set for rapid growth, presenting valuable opportunities for healthcare providers, researchers, and patients alike. Let’s explore the current market size, key factors propelling growth, leading players, and emerging trends shaping the future of tumor blood testing.
Rapid Expansion in Tumor Blood Testing Market Size
The tumor blood testing market has experienced strong growth recently and is projected to rise from $5.98 billion in 2025 to $6.78 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.3%. This increase during the historical period has been driven by factors such as the rising incidence of cancer, limitations associated with traditional tissue biopsies, advancements in genomic testing technologies, increased funding for oncology research, and heightened demand for non-invasive diagnostic methods. Looking ahead, the market is expected to grow even faster, reaching $11.13 billion by 2030 at a CAGR of 13.2%. Key drivers during the forecast period include the expansion of early cancer screening programs, the integration of AI-enabled genomic analysis, growth in personalized medicine, broader adoption of companion diagnostics, and increased utilization of clinical trials. Important trends shaping the future include wider liquid biopsy use, multi-cancer early detection technologies, monitoring minimal residual disease, personalized oncology testing, and advancements in high-sensitivity biomarker detection.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28343&type=smp
Factors Behind Tumor Blood Testing Market Expansion
One of the primary factors boosting growth in the tumor blood testing market is the increasing prevalence of cancer worldwide. Aging populations, along with exposure to risk factors such as unhealthy diets, smoking, and environmental pollution, have contributed to a surge in cancer cases. This, in turn, drives demand for early and accurate detection methods. Tumor blood testing offers a minimally invasive way to detect cancer biomarkers circulating in the bloodstream, allowing for earlier diagnosis before symptoms become evident. This enables timely therapeutic intervention, better patient outcomes, and ongoing disease monitoring. For example, in May 2024, the National Cancer Institute reported that as of January 2022, there were approximately 18.1 million cancer survivors in the United States, with projections estimating this number to rise to 26 million by 2040. This rising cancer population underscores the urgent need for improved diagnostic tools like tumor blood testing.
Key Revenue Drivers in Tumor Blood Testing Market Segmentation
The tumor blood testing market is segmented into various categories to better understand its dynamics:
– By Test Type: Circulating Tumor Cells (CTC) Tests, Circulating Tumor DNA (CtDNA) Tests, Exosome-Based Tests, and other types.
– By Technology: Polymerase Chain Reaction (PCR)-based testing, Next-Generation Sequencing, and Immunoassays.
– By Cancer Type: Breast, Colorectal, Lung, Prostate, and Melanoma cancers.
– By Application: Early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring.
– By End User: Hospitals, diagnostic laboratories, research institutes, and other users.
Access The Complete Tumor Blood Testing Market Report:
https://www.thebusinessresearchcompany.com/report/tumor-blood-testing-global-market-report
Within these segments are further subcategories such as CTC tests focusing on isolation, enumeration, and characterization of tumor cells; CtDNA tests analyzing mutations, methylation, copy number variations, and fragmentation; exosome-based tests profiling proteins, RNA, lipids, and surface markers; and other tests including circulating RNA assays, tumor-educated platelet tests, protein biomarker panels, multiomics blood tests, and immuno-oncology biomarker evaluations.
Emerging Technologies Shaping Tumor Blood Testing Market Growth
Leading companies in the tumor blood testing space are heavily focused on pioneering non-invasive liquid biopsy technologies to improve early cancer detection and treatment monitoring. These technologies analyze cancer-related biomarkers from body fluids, presenting a safer alternative to traditional tissue biopsies. For instance, in February 2024, Delfi Diagnostics, a US biotech firm, partnered with UK-based Immunocore Holdings to launch the DELFI-Tumor Fraction (DELFI-TF) assay. This blood test examines cell-free DNA fragments circulating in the blood to evaluate tumor burden and treatment response. The fragmentome-based liquid biopsy offers a cost-effective and minimally invasive option, requiring small plasma volumes and delivering results within two weeks, enhancing patient convenience and clinical decision-making.
Leading Organizations Driving Competition in Tumor Blood Testing Market
The tumor blood testing market is highly competitive, with several key players shaping its future. Prominent companies include Bio-Techne Corporation, Roche Holding AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Natera Inc., Myriad Genetics Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Foundation Medicine Inc., Adaptive Biotechnologies Corporation, Freenome Holdings Inc., Grail Inc., Personal Genome Diagnostics Inc., Exosome Diagnostics Inc., Agena Bioscience Inc., and Menarini Silicon Biosystems S.p.A. These organizations are investing heavily in research and development to create innovative products and expand the reach of tumor blood testing.
Regional Market Distribution Trends Driving Growth
In 2025, North America held the largest share of the tumor blood testing market, benefiting from advanced healthcare infrastructure and extensive research activities. Meanwhile, the Asia-Pacific region is anticipated to be the fastest-growing market during the forecast period, due to increasing healthcare investments, growing cancer awareness, and expanding diagnostic capabilities. Other key regions covered in the market report include South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa, each contributing uniquely to global market dynamics and expansion opportunities.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model